SUMMARY CSF immunoglobulins were examined in 103 patients with clinically definite multiple sclerosis, 106 patients with either suspected or progressive possible multiple sclerosis and 72 patients with other neurological diseases. Raised CSF IgG index and oligoclonal banding were found in 71% and 75% of clinically definite multiple sclerosis patients respectively and both tests were abnormal in 11% of patients with other neurological diseases. The CSF IgG index and the presence of oligoclonal IgG did not relate to the severity or duration of established disease in these patients. In patients with suspected and progressive possible multiple sclerosis, both a raised IgG index and the presence of oligoclonal banding were found significantly more frequently than in the OND group. Abnormalities of these parameters were significantly correlated with the presence of an abnormal evoked response in these patients (X2 = 10O16 p < 0-01). When 47 patients with suspected multiple sclerosis were studied prospectively the presence of oligoclonal banding at presentation was associated with development of further disease activity.
Although IgG estimation and electrophoresis in the cerebrospinal fluid (CSF) are well established as aids to the diagnosis of multiple sclerosis, the detection of oligoclonal banding has yielded variable results using differing techniques. ' -4 Polyacrylamide gel electrophoresis has been reported to be positive in 56% to 94% of patients with clinically definite multiple sclerosisS6 whereas isoelectric focusing with immunofixation has been claimed to be superior with up to 100% abnormalities in clinically definite multiple sclerosis. 78 More importantly two studies have shown that the detection of oligoclonal banding is of significance for the future development of clinically definite multiple sclerosis in patients with possible multiple sclerosis9 and optic neuritis.'0 An association of oligoclonal banding with abnormal evoked responses in patients with monosymptomatic demyelination has been described.9 Patients with benign multiple sclerosis have been reported to have a lower frequency of oligoclonal banding and lower IgG levels in the CSF in comparison to those patients with a more aggressive course."
In this study we have examined the role of IgG estimation, polyacrylamide gel electrophoresis (PAGE) and isoelectric focusing with immunofixation (IEF) in clinically definite multiple sclerosis and the relationship between CSF IgG abnormalities and disease severity in these patients. We have examined, the significance of the CSF IgG index and electrophoresis in progressive possible and suspected multiple sclerosis and the relationship to evoked response abnormalities. In patients with suspected multiple sclerosis the predictive value of oligoclonal banding was evaluated.
Patients an methods
Since 1980 all patients with a clinical diagnosis of multiple sclerosis who were admitted to two Dublin hospitals were surveyed. The multiple sclerosis patients were classified by 989 
Results
Abnormalities of CSF immunoglobulins in clinically definite multiple sclerosis (Table 1) There were 103 patients in this group. Oligoclonal banding and a raised CSF IgG index was found in 75% and 71% of multiple sclerosis patients respectively while both tests were abnormal in only 11% of the other neurological disease group. Although an abnormal IgG ratio was found in a high proportion of multiple sclerosis patients (82%), raised ratios were also found in 42% of the OND group. Thus, while the CSF IgG index and oligoclonal banding are supportive in the diagnosis of multiple sclerosis, the IgG ratio was of little value.
When patients were divided according to the presence or absence of CSF oligoclonal banding, there was no significant difference in age of onset, duration of illness or disability between the two groups. Similar CSF immunoglobulin abnormalities were found in 23 patients with benign multiple sclerosis (defined as having disability less or equal to three on the Kurtzke Scale after ten years of illness), when compared with nine patients with aggressive disease (defined as having disability greater than three on the Kurtzke Scale within five years of illness). In the benign group the mean CSF IgG index was 1k 1 and 19 were oligoclonal banding positive (83%), whereas in the patients with aggressive disease the mean CSF IgG index was 1-0 and eight patients were oligoclonal banding positive (89%).
Abnormalities of CSF immunoglobulins in suspected and progressive possible multiple sclerosis. (Table 1) There were 53 patients in the suspected group and of those examined 28% had a raised CSF IgG index which was significantly more than in the OND group (p < 0-05). 46% were oligoclonal banding positive compared with 11% of those with OND (p < 0.01). In the progressive possible group the frequency of oligoclonal banding (57%) was similar to the presence of an abnormal IgG index (55%) and both differed significantly from those with OND (X2= 10X16 p < 0.01).
All the patients in these two groups (106) Relationship between CSF IgG index, electrophoresis and diagnostic category of multiple sclerosis The close association between an abnormal CSF IgG index and oligoclonal banding is shown in the fig. This was significant for the entire patient population (X2 = 98 p < 0.001) and also for each of the three multiple sclerosis groups. It is clear from the scattergram that the frequency of CSF IgG abnormalities increased in multiple sclerosis as the clinical diagnosis became more certain.
When the two methods of electrophoresis used in this study were compared, IEF with immunofixation detected oligoclonal banding with a higher frequency than PAGE in patients with clinically definite multiple sclerosis (85% v 69%) and in the progressive possible group (90% v 29%). However this difference was only significant in the progressive possible patients (p < 0.01) ( Table 1) .
Discussion
This study confirms the presence of CSF immunoglobulin abnormalities in clinically definite multiple There is evidence that synthesis of CSF IgG increases during disease activity. '8 (table 2) . This relationship has been previously reported in "possible multiple sclerosis" by Moulin et al'9 and also by Bartel and his colleagues.
In the prospective study of patients with suspected multiple sclerosis 54% of those who were oligoclonal banding positive at presentation had further relapses and the majority of these had become clinically definite at follow up. Of the oligoclonal banding negative patients only 9*5% had further relapses. Moulin et al9 reported similar findings in patients with "possible multiple sclerosis". Twenty four percent of their patients who were oligoclonal banding positive developed further episodes, while only 9% of the oligoclonal banding negative group had a relapse. It has also been shown that in patients with optic neuritis the presence of CSF oligoclonal banding was associated with increased tendency to later dissemination of disease. '0 Patients with suspected multiple sclerosis who had abnormal ERs indicating a second lesion had a higher incidence of further disease activity at follow 993 up than those with normal ERs. This finding supports the work of Matthews et a120 who showed 50% of their patients with suspected multiple sclerosis with abnormal ERs at presentation developed clinically definite multiple sclerosis within three years. However in our prospective study the presence of CSF oligoclonal banding was more informative than that of abnormal ERs, since oligoclonal banding was present in a higher proportion of patients and was a better predictor of further disease activity.
